Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05290857
Other study ID # 3349 20210798-01H
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 31, 2022
Est. completion date December 2025

Study information

Verified date November 2023
Source Ottawa Hospital Research Institute
Contact Deborah M Siegal, MD
Phone 613-737-8899
Email dsiegal@toh.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PANTHER-GI Pilot Study will assess the feasibility of a full-scale multicentre cohort management study evaluating the safety of a standardized strategy for resuming direct oral anticoagulants (DOACs) after major DOAC-related gastrointestinal (GI) bleeding among patients at moderate to high risk of re-bleeding and thrombosis. A parallel registry will assess whether eligible patients who are not enrolled in the PANTHER-GI Pilot Study are systematically different than enrolled patients and to explore barriers to enrolment.


Description:

This pilot cohort management study will evaluate a protocolized strategy for resuming DOACs after major GI bleeding based on thrombotic risk among patients at moderate to high risk of rebleeding. The timeframe for resuming DOACs will be determined based on the patient's underlying thrombotic risk.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 2025
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female subjects aged 18 years or older 2. Hospitalized with acute major non-variceal GI bleeding (defined as per ISTH criteria) while receiving OAC therapy (warfarin or DOAC). 3. OAC therapy discontinued for current acute GI bleed and not yet resumed 4. Ongoing indication for long-term anticoagulation of atrial fibrillation (moderate to high risk of stroke/systemic embolism with CHA2DS2VASc score of 3 or higher) or VTE (as per clinical care team) 5. Planned to resume DOAC post-bleed 6. At moderate to high risk of re-bleeding as per clinical care team 7. Clinical hemostasis achieved as per clinical care team 8. Able and willing to comply with follow-up examinations contained within the consent form Exclusion Criteria: 1. Mechanical heart valve 2. VTE in the context of major transient risk factor and completed 3 months of treatment 3. GI bleeding managed surgically (e.g. gastrectomy, colectomy) 4. Active or previously treated gastrointestinal cancer 5. Life expectancy from other causes of less than 3 months 6. Platelet count < 50,000/µL (or < 50x109/L) 7. Renal dysfunction (Creatine Clearance <30 mL/min as calculated by the Cockcroft-Gault formula)

Study Design


Intervention

Other:
Restart DOAC within 7 days of clinical hemostasis after GI bleeding
In patients at high thrombotic risk, DOACs will be resumed within 7 days of clinical hemostasis (as judged by the clinical team). High thrombotic risk includes the following: (i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 5 or higher (ii) Atrial fibrillation or atrial flutter with CHA2DS2VASc score or 3 to 4 with recent ischemic stroke, TIA or systemic embolism (within 6 months) (iii) VTE (proximal DVT or PE) within 3 months (iv) Recurrent VTE (proximal DVT or PE) (v) VTE (proximal DVT or PE) associated with antiphospholipid syndrome (if eligible for DOAC) (vi) VTE (proximal DVT or PE) associated with active non-GI cancer (vii) None of the above but considered high thrombotic risk as per investigator
Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding
In patients at moderate thrombotic risk, DOACs will be resumed between 7 and 14 days of clinical hemostasis (as judged by the clinical team). Moderate thrombotic risk includes the following: (i) Atrial fibrillation or atrial flutter with CHA2DS2VASc score of 3 to 4 (ii) VTE (proximal DVT or PE) beyond 3 months The type and dose of DOAC will be according to patient and physician choice and will be prescribed by the clinical care team.

Locations

Country Name City State
Canada Alberta Health Services - Peter Lougheed Center Endoscopy Unit Calgary Alberta
Canada Ottawa Hospital Research Institute Ottawa Ontario

Sponsors (1)

Lead Sponsor Collaborator
Ottawa Hospital Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recruitment rate The pilot study will be considered a success and to have demonstrated feasibility if average recruitment of 2 patients per month at each site is achieved. 18 months
Primary Total recruitment Feasibility criterion of achieving recruitment of 85% of the target sample size of 100 patients 18 months
Secondary eligibility proportion of patients screened who are eligible to participate out of all patients screened 18 months
Secondary consent proportion of eligible patients who provide consent to participate out of all eligible patients 18 months
Secondary completion of all required study procedures proportion of patients who complete all required study procedures out of all enrolled patients 18 months
Secondary adherence proportion of patients who adhere to study treatment strategy (i.e. resumed DOAC within the specified timeframe) out of the total number of patients enrolled 18 months
Secondary repeat endoscopy proportion of patients with repeat endoscopy for suspected bleeding after index GI bleed out of all enrolled patients 90 days
Secondary re-hospitalization number of patients re-hospitalization for GI bleeding after index GI bleed out of all patients enrolled 90 days
Secondary major bleeding number of patients with major bleeding (as per International Society on Thrombosis and Haemostasis [ISTH] criteria) out of all patients enrolled 90 days
Secondary clinically relevant non-major bleeding number of patients with clinically relevant non-major bleeding (CRNMB; as per ISTH) out of all patients enrolled 90 days
Secondary acute ischemic stroke, transient ischemic attack or systemic embolism number of patients who experience composite of acute ischemic stroke, transient ischemic attack or systemic embolism our of all patients enrolled 90 days
Secondary acute symptomatic VTE number of patients with acute objectively confirmed venous thromboembolism (symptomatic proximal lower extremity deep vein thrombosis [DVT], symptomatic pulmonary embolism [PE] as per ISTH) out of all patients enrolled 90 days
Secondary net clinical benefit outcome rate number of patients experiencing composite of stroke, systemic embolic event, major bleeding, or death from any cause out of all patients enrolled 90 days
Secondary all-cause mortality number of patients who die of all causes out of all patients enrolled 90 days
Secondary functional status Change in functional status measured using Standard Assessment of Global Activities in the Elderly (SAGE) scale at 90 days compared to baseline.
SAGE is a 15-item scale that represents a measure of activities of daily living (ADL) across the spectrum of functioning (cognitive, instrumental and basic ADL). The SAGE is supplemented with additional measures of cognition, mood, and quality of life.
The minimum SAGE score - which corresponds to no functional impairments - is 0. The maximum SAGE score - which corresponds to severe global functional impairment - is 45.
90 days
Secondary Quality of life of Panther GI Research participants Quality of life measured using EuroQol-5D [EQ-5D®] at 90 days compared to baseline.
The EQ-5D instrument comprises a descriptive system questionnaire and a visual analogue scale (EQ VAS). The questionnaire provides a descriptive profile of a respondent's health state representing the level of reported problems on each of the five dimensions of health (mobility, self-care, usual activities, pain or discomfort, anxiety/depression) that can be converted into a single index value. Average index values (expressed as mean and standard deviation or median and interquartile range depending on skewness) at 90 days will be compared to baseline.
The EQ VAS elicits an individual's rating of their own overall current health (0-100 scale where 0 is the worst health you can imagine and 100 is best health you can imagine). Average EQ VAS ratings (expressed as mean and standard deviation or median and interquartile range depending on skewness) at 90 days will be compared to baseline.
90 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05060731 - Iron Supplementation in Upper Non-variceal Gastrointestinal Bleeding Phase 4
Recruiting NCT05949268 - Video Capsule Endoscopy for Detection of Gastrointestinal Bleeding in the Small Bowel
Not yet recruiting NCT03243240 - Computed Tomography in Gastrointestinal Bleeding N/A
Completed NCT02595853 - Efficacy of a Novel Hemostatic Powder in GI Bleeding
Completed NCT01434108 - Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding Phase 2/Phase 3
Terminated NCT01756690 - Predicting Lung Injury From Transfusion in Patients With Liver Disease N/A
Completed NCT01424254 - The Effectiveness of Video-capsule Endoscopy in Gastrointestinal Bleeding of Obscure Origin Phase 3
Completed NCT05884931 - Effectiveness and Safety of Nexpowder as an Endoscopic Hemostatic Treatment N/A
Completed NCT01335516 - Follow-up of Glypressin (Terlipressin) Clinical Efficacy in the Treatment of Bleeding Oesophageal Varices N/A
Withdrawn NCT00401908 - Factors Contributing To Cardiovascular Morbidity and Mortality in Patients With Gastrointestinal Bleeding N/A
Recruiting NCT05024864 - HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in MI Patients N/A
Completed NCT05008640 - Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™
Recruiting NCT06259292 - Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Completed NCT03716466 - Evaluation of Prophylactic Endotracheal Intubation
Completed NCT05362227 - High-Volume Vs Low-Volume Preparation in Emergency Department N/A
Completed NCT02405286 - Prospective Assessment of the Rockall Risk ScoringSystem in Patients With Upper Gastrointestinal Hemorrhage N/A
Recruiting NCT00562445 - Adrenal Insufficiency in Critical Emergencies in Digestive Diseases N/A
Recruiting NCT02863250 - Australian and New Zealand Massive Transfusion Registry
Completed NCT01415869 - Occult Gastrointestinal Bleeding in Non-pulsatile Left Ventricular Assist Device(VAD)Patients
Completed NCT01821326 - Risk Factors for Rebleeding in Patients With Obscure Gastrointestinal Bleeding N/A